Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 D'Addario, 2010, Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, 21, v116, 10.1093/annonc/mdq189 Siegel, 2012, Cancer statistics, 2012, CA Cancer J Clin, 62, 10, 10.3322/caac.20138 Little, 2005, Patterns of surgical care of lung cancer patients, Ann Thorac Surg, 80, 2051, 10.1016/j.athoracsur.2005.06.071 Johnson, 2011, Accelerated approval of oncology products: the food and drug administration experience, J Natl Cancer Inst, 103, 636, 10.1093/jnci/djr062 Rosell, 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 239, 10.1016/S1470-2045(11)70393-X Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699 Soria, 2010, Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?, Ann Oncol, 21, 2324, 10.1093/annonc/mdq204 Buyse, 2008, Individual- and trial-level surrogacy in colorectal cancer, Stat Methods Med Res, 17, 467, 10.1177/0962280207081864 1995, Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials, BMJ, 311, 899, 10.1136/bmj.311.7010.899 Auperin, 2010, Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer, J Clin Oncol, 28, 2181, 10.1200/JCO.2009.26.2543 2010, Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data, Lancet, 375, 1267, 10.1016/S0140-6736(10)60059-1 Le Pechoux, 2008, Individual patient data (IPD) meta-analysis (MA) of chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC), J Thorac Oncol, 3, 35IN Mauguen, 2012, Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis, J Clin Oncol, 30, 2788, 10.1200/JCO.2012.41.6677 Burzykowski, 2001, Validation of surrogate end points in multiple randomized clinical trials with failure time end points, J R Stat Soc Ser C Appl Stat, 50, 405, 10.1111/1467-9876.00244 Buyse, 2000, The validation of surrogate endpoints in meta-analyses of randomized experiments, Biostatistics, 1, 49, 10.1093/biostatistics/1.1.49 Sargent, 2005, Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20 898 patients on 18 randomized trials, J Clin Oncol, 23, 8664, 10.1200/JCO.2005.01.6071 Michiels, 2009, Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data, Lancet Oncol, 10, 341, 10.1016/S1470-2045(09)70023-3 Lassere, 2008, Stat Methods Med Res, 17, 303, 10.1177/0962280207082719 Burzykowski, 2006, Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation, Pharm Stat, 5, 173, 10.1002/pst.207 Stone, 2011, Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group, Eur J Cancer, 47, 1763, 10.1016/j.ejca.2011.02.011 Buyse, 2007, Progression-free survival is a surrogate for survival in advanced colorectal cancer, J Clin Oncol, 25, 5218, 10.1200/JCO.2007.11.8836 Burzykowski, 2008, Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer, J Clin Oncol, 26, 1987, 10.1200/JCO.2007.10.8407 Laporte, 2013, Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials, BMJ Open, 3, e001802, 10.1136/bmjopen-2012-001802 Foster, 2011, Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials, Cancer, 117, 1262, 10.1002/cncr.25526 Broglio, 2009, Detecting an overall survival benefit that is derived from progression-free survival, J Natl Cancer Inst, 101, 1642, 10.1093/jnci/djp369 Saad, 2012, Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure?, J Clin Oncol, 30, 1750, 10.1200/JCO.2011.38.6359 2000, Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials, Lancet, 355, 1757, 10.1016/S0140-6736(00)02263-7